Genscript Biotech (HKSE:01548) FCF Margin % : -27.52% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Genscript Biotech's Free Cash Flow for the six months ended in Dec. 2023 was HK$-963 Mil. Genscript Biotech's Revenue for the six months ended in Dec. 2023 was HK$3,500 Mil. Therefore, Genscript Biotech's FCF Margin % for the quarter that ended in Dec. 2023 was -27.52%.

As of today, Genscript Biotech's current FCF Yield % is -13.09%.

The historical rank and industry rank for Genscript Biotech's FCF Margin % or its related term are showing as below:

HKSE:01548' s FCF Margin % Range Over the Past 10 Years
Min: -71.34 Med: -29.36 Max: 98.72
Current: -53

During the past 10 years, the highest FCF Margin % of Genscript Biotech was 98.72%. The lowest was -71.34%. And the median was -29.36%.

HKSE:01548's FCF Margin % is ranked better than
61.48% of 1041 companies
in the Biotechnology industry
Industry Median: -145.04 vs HKSE:01548: -53.00

Genscript Biotech FCF Margin % Historical Data

The historical data trend for Genscript Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech FCF Margin % Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-54.32

-71.34

-55.60

-51.76

-52.96

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial														-63.42	-46.68	-56.74	-82.10	-27.52

Competitive Comparison of Genscript Biotech's FCF Margin %

For the Biotechnology subindustry, Genscript Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genscript Biotech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genscript Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Genscript Biotech's FCF Margin % falls into.

Genscript Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Genscript Biotech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3472.425	/	6556.554
	=	-52.96 %

Genscript Biotech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-963.276	/	3500.493
	=	-27.52 %

Genscript Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Genscript Biotech (HKSE:01548) Headlines

No Headlines